Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanna M Rybak

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Molecular Biotechnology|March 6, 2002
Preparation of recombinant RNase single-chain antibody fusion proteinsDianne L Newton, Susanna M Rybak
FEBS Letters|December 14, 2004
Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimersMichaela A E Arndt, Jürgen Krauss, Susanna M Rybak
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
Anti-CD22 Onconase: preparation and characterizationDianne L Newton, Luke H Stockwin, Susanna M Rybak
Methods in Molecular Biology (Clifton, N.J.)|November 5, 2002
Construction and characterization of RNase-based targeted therapeuticsDianne L Newton, Junichiro Futami, Dale Ruby, et al.
Journal of Molecular Biology|March 28, 2002
Crystallographic and functional studies of a modified form of eosinophil-derived neurotoxin (EDN) with novel biological activitiesChangsoo Chang, Dianne L Newton, Susanna M Rybak, et al.
Current Pharmaceutical Biotechnology|August 5, 2008
Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapyJürgen Krauss, Michaela A E Arndt, Stefan Dübel, et al.
Expert Opinion on Biological Therapy|December 10, 2008
Targeted therapeutic RNases (ImmunoRNases)Thomas Schirrmann, Jürgen Krauss, Michaela A E Arndt, et al.
British Journal of Haematology|February 24, 2005
Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymeJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Protein Engineering|November 6, 2003
Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragmentJürgen Krauss, Michaela A E Arndt, Andrew C R Martin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cellsMichaela A E Arndt, Jürgen Krauss, Bang K Vu, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Molecular Biotechnology|March 6, 2002
Preparation of recombinant RNase single-chain antibody fusion proteinsDianne L Newton, Susanna M Rybak
FEBS Letters|December 14, 2004
Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimersMichaela A E Arndt, Jürgen Krauss, Susanna M Rybak
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
Anti-CD22 Onconase: preparation and characterizationDianne L Newton, Luke H Stockwin, Susanna M Rybak
Methods in Molecular Biology (Clifton, N.J.)|November 5, 2002
Construction and characterization of RNase-based targeted therapeuticsDianne L Newton, Junichiro Futami, Dale Ruby, et al.
Journal of Molecular Biology|March 28, 2002
Crystallographic and functional studies of a modified form of eosinophil-derived neurotoxin (EDN) with novel biological activitiesChangsoo Chang, Dianne L Newton, Susanna M Rybak, et al.
Current Pharmaceutical Biotechnology|August 5, 2008
Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapyJürgen Krauss, Michaela A E Arndt, Stefan Dübel, et al.
Expert Opinion on Biological Therapy|December 10, 2008
Targeted therapeutic RNases (ImmunoRNases)Thomas Schirrmann, Jürgen Krauss, Michaela A E Arndt, et al.
British Journal of Haematology|February 24, 2005
Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymeJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Protein Engineering|November 6, 2003
Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragmentJürgen Krauss, Michaela A E Arndt, Andrew C R Martin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cellsMichaela A E Arndt, Jürgen Krauss, Bang K Vu, et al.
Pageof 2